An innovative solution for the treatment of early medial compartment osteoarthritis of the knee
OSTESYS is a company founded in March 2009 by researchers from the LaTIM laboratory (Laboratory of Medical Information Processing), international surgeons (France, UK, USA), and experienced business managers.
OSTESYS designs an innovative solution for the treatment of early medial compartment osteoarthritis of the knee in orthopaedic surgery.
Pr. Eric STINDEL, Ostesys scientific and clinical consultant, was awarded the Maurice E. Muller Award 2015 for his work on computer assisted orthopedic surgery since 2000. Link to the article.
January 2015, Ostesys in "Le Télégramme" - local newspaper - link to the article.
June 2014, Pierre-Yves was at the press reception “Cutting-edge medical research: Finistère, a laboratory for innovation” and presented the OSTESYS technology.
December 2013, the technology has been validated in cadaver labs tests in France by Pr. Eric Stindel and Pr. Christian Lefevre and in USA by Dr. James Stiehl, Dr. Leela Biant, Dr. Matthew Matava and Dr. Robert Brophy
July 2013, Ostesys raises 200,000€ from business angels
March 2013, Ostesys managers attend AAOS Congress in Chicago and obtain very positive feedback from several potential partners & US surgeons
February 2013, Ostesys raises love money from experts in the domain
In 2008, Stéphane Lavallée, PhD, an experienced entrepreneur in Computer Assisted Surgery, and Professor Eric Stindel, MD, PhD, who is considered one of the top international clinical experts in computer assisted orthopedic surgery, analyzed the markets and available technologies in early arthritis treatment, and realized there was a huge opportunity in developing and marketing a solution entirely focused on computer-assisted tibial osteotomies. They decided to partner and found a company reflecting their vision. At that time, Guillaume Dardenne was finishing his PhD thesis at Telecom Bretagne and was considered the best PhD engineer of his generation in this field. Immediately, Guillaume Dardenne embraced the project with enthusiasm. The team was then joined by two highly experienced Professors, one on the clinical side, Pr Christian Lefevre, MD, Brest Hospital, and the other on the scientific side, Pr. Christian Roux, PhD., Telecom Institute, both bringing a clinical and scientific network and a solid experience in surgical techniques, medical imaging and innovations.
In 2009, the OSTESYS project took off and benefitted, from the outset, from the support of Brest University (UBO), Brest Hospital (CHU) and the Telecom Institute, with the objective of fine-tuning the market analysis, the IP analysis and the technology concept. The company OSTESYS was incorporated on March 25th 2009, in the outskirts of Brest.
In 2010, OSTESYS received a 125,000€ grant from the French Ministry of Research and Education (“Oseo Création Développement”).
OSTESYS is perceived by many experts and specialists as a future champion and has received several prizes and honors. From 2009 to 2011, OSTESYS has designed several HTO implants and instruments. All these solutions have shown flaws.
In 2011, Pierre-Yves Huet joined the R&D team as mechanical project manager and was in charge of the design of the instrument and implants.
At the beginning of 2012, three famous US orthopedic surgeons and one UK orthopedic surgeon decided to join the OSTESYS team: Dr James Stiehl, MD, Dr Matthew Matava, MD, Dr Robert Brophy, MD for the USA and Dr Leela Biant, MD.
At the end of 2012, OSTESYS designed “THE” solution for its HTO project. To become a highly successful product, the technology has just needed fine-tuning.
In 2013, Pierre-Yves has been nominated CEO of OSTESYS because of exceptional efficiency recognized by the initial founders.
The current technology has already been validated during year 2013 and 2014, on anatomical specimens in cadaver labs of Saint Louis (USA) and Brest (France). This technology is extremely well perceived by our experts.
This product is being industrialized in order to obtain CE marking and FDA approval.